Loading company…
Xinglian Biotechnology researches and develops protein-coupled drugs for tumors.
Based in Tianjin, China, Xinglian Biotechnology researches and develops protein-coupled drugs, with product pipelines intended for tumor treatment. It combines external product introductions with in-house research and development. The company raised CNY 55 million in angel funding in February 2023 and CNY 100 million in pre-Series A+ funding in January 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in